Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Sanofi Planning High-Level Changes At India's Vaccines Unit Shantha? A Leading Biocon Scientist Joins Shantha

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Two years after it bagged Indian vaccines specialist Shantha Biotechnics Ltd. with an aim to develop low-cost vaccines, Sanofi is set to rollout significant changes in the management of its acquired Hyderabad site in Central India

You may also be interested in...



India’s Expanding Vaccines Market Offers Promise To Global And Local Drug Firms (Part 2 of 2)

Several drug companies are gearing up to go full throttle into the Indian vaccines market with programs that go beyond pushing products and seek to build up public health awareness on a larger scale. GSK, Sanofi, Merck, Novartis and Pfizer are in the fray with local players Serum Institute of India, Bharat Biotech, and Panacea Biotec.

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel